ARMGO Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.armgo.com
Treatment of an Inherited Ventricular Arrhythmia
Phase 2
Recruiting
- Conditions
- Catecholaminergic Polymorphic Ventricular Tachycardia Type 1
- Interventions
- Drug: S48168 (ARM210)Drug: Matching Placebo
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Armgo Pharma, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05122975
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇳🇱Amsterdam University Medical Center, Amsterdam-Zuidoost, Netherlands
S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Armgo Pharma, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04141670
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath